Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Pfizer

Related PFE
15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference
Pfizer Is At A 'Strategic Crossroads'
Stock Indexes Pad Recent Gains; Daily Volume, Though, Declines (Investor's Business Daily)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “The 5% revenue miss in Q3'12 was forgiven to a degree as Lipitor phasing was partly to blame and EPS was still delivered through financial engineering. Lighter than expected Prevnar-13 and Enbrel sales were more concerning, though we now have the US launches of tofacitinib and hopefully Eliquis within the next 3-6 months to look forward to. New product launches, share repurchases and restructuring drive near term upside in our view.”

Pfizer closed on Friday at $24.16.

Latest Ratings for PFE

Dec 2015BarclaysAssumesEqual-weight
Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters